Summary
The pharmacokinetics of theophylline was investigated in five hyperthyroid, five hypothyroid, and five euthyroid patients, all with chronic obstructive pulmonary disease. Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel=0.155, 0.060 and 0.107 h−1, respectively). The values for clearance and volume of distribution were not consistently changed compared with those in the euthyroid group, although all the parameters except AUC were significantly different in hyperthyroid and hypothyroid patients. There was a positive correlation between both thyroxine and triiodothyronine serum concentrations and total body clearance of theophylline (r=0.795 and r=0.791, respectively). It is concluded that in spite of the wide interindividual variability and the relatively small differences in the pharmacokinetics of theophylline in thyroid dysfunction compared with the euthyroid status, these differences have to be considered in certain clinical situations, as they may require changes in the therapeutic regimen for administration of theophylline in hyperthyroid or hypothyroid patients.
Similar content being viewed by others
References
Eichelbaum M (1983) Drug metabolism in thyroid disease. In: Gibaldi M, Prescott L (eds) Handbook of clinical pharmacokinetics. ADIS Health Science Press, New York, pp 169–181
Bauman JH, Teichman S, Wible DA (1984) Increased theophylline clearance in a patient with hyperthyroidism. Ann Allergy 52: 94–96
Aderka D, Shavitt G, Garfinkel D, Santo M, Gitter S, Pinkhas J (1983) Life-threatening theophylline intoxication in a hypothyroid patient. Respiration 44: 77–80
Vozeh S, Otten M, Staub J-J, Follath F (1984) Influence of thyroid function on theophylline kinetics. Clin Pharmacol Ther 36: 634–640
Pokrajac M, Varagić VM (1983) Spectrodensitometric determination of theophylline in plasma. Acta Pharm Jugosl 33: 23–28
Pokrajac M, Agbaba D, Varagić VM, Glišović L (1986) The comparison of the spectrodensitometric determination of theophylline to HPLC, RIA and EMIT procedures. Acta Pharm Jugosl 36: 445–453
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York
Shenfield GM (1981) Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 6: 275–297
Crooks J, Hedley AJ, Macnee C, Stevenson IH (1973) Changes in drug metabolizing ability in thyroid disease. Br J Pharmacol 49: 156P-157P
Dan-Shya Tang-Liu D, Williams RL, Riegelman S (1982) Nonlinear theophylline elimination. Clin Pharmacol Ther 31: 358–369
Jenne JW (1982) Theophylline. A remarkable window to the hepatic microsomal oxidases. Chest 81: 529–530
Eichelbaum M, Bodem G, Gugler R, Schneider-Deters C, Dengler HJ (1974) Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med 290: 1040–1042
Vesell ES, Shapiro JR, Thomas Passananti G, Jorgensen H, Shively CA (1975) Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther 17: 48–56
Feely J, Crooks J, Stevenson IH (1981) Plasma propranolol steady state concentrations in thyroid disorders. Eur J Clin Pharmacol 19: 329–333
Feely J, Stevenson IH, Crooks J (1981) Increased clearance of propranolol in thyrotoxicosis. Ann Intern Med 94: 472–474
Aro A, Anttila M, Korhonen T, Sundquist H (1982) Pharmacokinetics of propranolol and sotalol in hyperthyroidism. Eur J Clin Pharmacol 21: 373–377
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pokrajac, M., Simić, D. & Varagić, V.M. Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 33, 483–486 (1987). https://doi.org/10.1007/BF00544240
Issue Date:
DOI: https://doi.org/10.1007/BF00544240